Drug Profile
AZD 4785
Alternative Names: AZD-4785; IONIS-KRAS-2.5RxLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer AstraZeneca; Ionis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides; Nucleotides; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Apr 2019 Discontinued - Phase-II for Solid tumours (Late-stage disease, Metastatic disease) in United Kingdom, USA (IV) (AstraZeneca pipeline, April 2019)
- 08 Jan 2019 AstraZeneca completes a phase I trial in Solid tumours (Late stage, Metastatic disease) in USA and United Kingdom (IV) (NCT03101839)
- 29 Aug 2018 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA and United Kingdom (IV) (Ionis Pharmaceuticals pipeline, August 2018)